Dr Ruby Singh

Dr Ruby Singh is a senior regulatory review scientist at the Center for Veterinary medicine, United States Food and Drug Administration (FDA).  Dr Singh’s area of expertise is in regulatory policies that are aimed at assessing the relationships between antimicrobial uses in veterinary medicine and the potential consequences to human health. Her current work focuses on the pre-approval review of complex qualitative and quantitative food safety risk assessments for new antimicrobial drugs. In addition, Dr Singh works very closely with the regulated pharmaceutical industry, other government agencies, academia, and the public by helping develop policies and guidelines on mitigating antimicrobial resistance (AMR) risks to humans, including the development and implementation of strategies to improve food safety and the stewardship of antimicrobial drug use in veterinary medicine. Dr Singh is currently the lead on revising FDA’s list of medically important antimicrobials and serves as a technical expert on the Codex Task Force on AMR, the Transatlantic task force on AMR and the U.S. National action plan on Combatting Resistance Bacteria. Dr Singh has also served as a past expert on the WHO Advisory Group on Integrated Surveillance of AMR (AGISAR).